MarketCap
Facebook
X
Telegram
Medpace Holdings DSO Ratio | MEDP
Annual DSO Ratio Medpace Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 50.4 | 51.5 | 53.4 | 55 | 55.5 | 62.4 | 66 | 69.1 | 69.5 | 69.1 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 69.5 | 50.4 | 60.2 |
Quarterly DSO Ratio Medpace Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54 | 51.4 | - | 51.9 | 51.1 | 48.6 | - | 52.4 | 50.1 | 51.6 | - | 52.6 | 52.8 | 53.7 | - | 29.6 | 29.2 | 56.7 | - | 53.7 | 52.7 | 56.3 | - | 63.8 | 71.7 | 62.6 | 61.8 | 65.7 | 66.3 | 65.7 | 63.4 | 67.9 | 71.6 | 60.6 | 67.3 | 68.5 | 71.4 | 69.7 | - | 67.5 | 68.7 | 66.4 | - | 32.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71.7 | 29.2 | 57.8 |
DSO Ratio of other stocks in the Diagnostics research industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
50.3 | - | -8.98 % | $ 14.8 K |  USA |
 |
QIAGEN N.V.
QGEN
|
30.8 | - | - | $ 10.6 B |  Niderland |
 |
Centogene N.V.
CNTG
|
145 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Charles River Laboratories International
CRL
|
65 | $ 280.05 | 0.13 % | $ 13.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
44.9 | $ 234.4 | 0.08 % | $ 26 B | USA |
 |
Biomerica
BMRA
|
57.7 | $ 1.58 | 3.18 % | $ 3.63 M | USA |
 |
DarioHealth Corp.
DRIO
|
56.7 | $ 7.59 | 3.48 % | $ 30.2 M |  Israel |
 |
Aspira Women's Health
AWH
|
1.17 K | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
94.7 | $ 1.4 | 0.68 % | $ 1.86 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
90.8 | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
DexCom
DXCM
|
87 | $ 89.75 | 0.75 % | $ 35 B | USA |
 |
Accelerate Diagnostics
AXDX
|
72.7 | - | -61.36 % | $ 2.46 M | USA |
 |
Interpace Biosciences
IDXG
|
66.9 | $ 1.66 | 0.6 % | $ 7.34 M | USA |
 |
Biocept
BIOC
|
112 | - | -13.05 % | $ 7.29 M | USA |
 |
Global Cord Blood Corporation
CO
|
112 | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
67.2 | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
11.7 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
122 | - | 0.12 % | $ 80.1 M | China |
 |
Chembio Diagnostics
CEMI
|
66.3 | - | 0.22 % | $ 16.8 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
98.1 | - | - | $ 10.7 B | USA |
 |
DermTech
DMTK
|
80.6 | - | -11.32 % | $ 2.94 M | USA |
 |
Exact Sciences Corporation
EXAS
|
30.8 | - | - | $ 19.8 B | USA |
 |
Heska Corporation
HSKA
|
40.8 | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
101 | - | -20.0 % | $ 1.06 M | USA |
 |
Soleno Therapeutics
SLNO
|
27 | - | - | $ 2.69 B | USA |
 |
Psychemedics Corporation
PMD
|
57.4 | - | -1.84 % | $ 15.3 M | USA |
 |
Motus GI Holdings
MOTS
|
77.2 | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
63.4 | $ 163.15 | 0.19 % | $ 12.8 B |  Irlanda |
 |
Syneos Health
SYNH
|
32.3 | - | - | $ 4.46 B | USA |
 |
Invitae Corporation
NVTA
|
242 | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
86.4 | - | -2.3 % | $ 19.4 M | USA |
 |
IQVIA Holdings
IQV
|
73.9 | $ 236.66 | 0.28 % | $ 40.7 B | USA |
 |
OpGen
OPGN
|
1.68 | - | -16.95 % | $ 1.54 M | USA |
 |
T2 Biosystems
TTOO
|
91.3 | - | -39.35 % | $ 313 K | USA |
 |
Anixa Biosciences
ANIX
|
385 | $ 3.18 | 0.93 % | $ 103 K | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Meridian Bioscience
VIVO
|
55.2 | - | - | $ 1.49 B | USA |
 |
ENDRA Life Sciences
NDRA
|
7.11 | $ 4.47 | 1.36 % | $ 3.52 M | USA |
 |
Quotient Limited
QTNT
|
54.9 | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Renalytix AI plc
RNLX
|
15.9 | - | 5.66 % | $ 22.7 M | Britain |
 |
Natera
NTRA
|
48.3 | $ 309.93 | 1.04 % | $ 42.4 B | USA |
 |
Myriad Genetics
MYGN
|
52.3 | $ 3.03 | 0.62 % | $ 281 M | USA |
 |
NeoGenomics
NEO
|
77.7 | $ 15.94 | 0.24 % | $ 2.04 B | USA |
 |
National Research Corporation
NRC
|
29.4 | $ 21.19 | 0.84 % | $ 474 M | USA |
 |
Surmodics
SRDX
|
34.9 | - | - | $ 608 M | USA |
 |
Quidel Corporation
QDEL
|
116 | $ 14.3 | 1.75 % | $ 602 M | USA |